? BIOINFORMATICS SHARED RESOURCE (BISR) The BISR is an essential shared resource that supports a wide range of studies with bioinformatics and computational biology needs, ranging from next generation sequencing (NGS) to data management in population science studies. Housed within the Department of BMI, the BISR's goal is to leverage a variety of informatics services, ranging from analysis of omics datasets to patient/participant-centered data instrumentation, access, and management tools and processes.
The Specific Aims of the BSR are to: 1) Provide state of the art bioinformatics and computational biology services; and 2) Provide OSUCCC investigators with services, expertise and access to technology platforms in support of heterogeneous and multi-dimensional biomedical data management requirements. Over the current grant cycle, Drs. Kevin Coombes (TT) and Lang Li (CB) assumed leadership of BISR, replacing Drs. Philip Payne and Jeffrey Parvin. During the current funding cycle, a Memorandum of Understanding (MOU) was established for the Department of Biomedical Informatics (BMI) and the OSUCCC to support 5 faculty at 10% per year for 3 years within BISR as they transition to grant funding, on a rolling basis, to provide non-chargeable, cancer focused bioinformatics work for OSUCCC membership and/or cancer focused researchers. Additional major changes for BISR include supporting the enhancement of the Genomics Shared Resource (GSR) to incorporate newly developed shared services with Nationwide Children's Hospital (NCH); and added capabilities to support studies involving data from single-cell sequencing, long-read (third generation) sequencing, metabolomics, and metagenomics. BISR has added five new faculty to support the areas of (1) computational optimization for drug sensitivity prediction (Cheng), (2) proteomics, and functional annotation of DNA non-coding regions (Zhang), (3) metabolomics and metagenomics (Mathe), (4) single-cell sequencing (Ma), and (5) long-read sequencing (Au). BISR supported Biospecimen Services Shared Resource (BSSR) projects (Total Cancer Care [TCC] and the Oncology Research Information Exchange Network [ORIEN]) by establishing a data warehouse of patient records with de-identified data. During the current funding cycle, the BISR supported 115 publications (25 > 10 impact factor), 134 users, and 32 NCI grants including 5 P01s, 2 P50s, 13 R01s, 3 R21s, 1 R50, 2 U01s, 1 U10, 1 UG1, involving members from all five programs. Over the next grant cycle, BISR will enhance services for ?integromics?, e.g., the integration of disparate source of both omics and clinical data. BISR will be a critical part of the Immune Monitoring and Discovery Platform (IMDP), an overarching approach for fostering interactions among shared resources for complex immuno-oncology projects. The annual budget of the BISR is $1,122,279, yet the CCSG request is $106,905. As such, the BISR leverages extensive institutional support and seeks only 9.5% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090004
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137
Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Nyankima, A Gloria; Rojas, Juan D; Cianciolo, Rachel et al. (2018) In Vivo Assessment of the Potential for Renal Bio-Effects from the Vaporization of Perfluorocarbon Phase-Change Contrast Agents. Ultrasound Med Biol 44:368-376

Showing the most recent 10 out of 2602 publications